Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Tax Provisions (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Tax Provisions for 6 consecutive years, with $40.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 5461.81% year-over-year to $40.0 million, compared with a TTM value of $36.7 million through Dec 2025, up 11368.12%, and an annual FY2025 reading of $36.7 million, up 11368.12% over the prior year.
  • Tax Provisions was $40.0 million for Q4 2025 at Cytek Biosciences, up from -$2.3 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $40.0 million in Q4 2025 and bottomed at -$2.8 million in Q1 2024.
  • Average Tax Provisions over 5 years is $1.8 million, with a median of $93000.0 recorded in 2021.
  • The sharpest move saw Tax Provisions tumbled 2390.0% in 2022, then surged 5461.81% in 2025.
  • Year by year, Tax Provisions stood at $1.6 million in 2021, then plummeted by 75.39% to $396000.0 in 2022, then crashed by 451.52% to -$1.4 million in 2023, then surged by 151.72% to $720000.0 in 2024, then soared by 5461.81% to $40.0 million in 2025.
  • Business Quant data shows Tax Provisions for CTKB at $40.0 million in Q4 2025, -$2.3 million in Q3 2025, and -$1.2 million in Q2 2025.